Scienmag

MAY 27, 2021

New Penn Medicine study shows how T cells compensate when other immune cells go down PHILADELPHIA–Antibodies aren’t the only immune cells needed to fight off COVID-19 — T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with […]. (..)

Antibody 54

Antibody Medicine Clinical Trials Clinical Trials 54

Scienmag

MAY 27, 2021

A special type of antibody is produced in patients who’ve had COVID-19 as well as less-serious coronaviruses that cause colds. LA JOLLA, CA–Even before the COVID-19 pandemic, most people in the United States already had been sick with a coronavirus, albeit a far less dangerous one.

Antibody 50

Antibody Vaccination Vaccine Allergies 50

Scienmag

FEBRUARY 25, 2021

Research from the California Institute of Technology shows exactly how antibodies stick to and block the Zika virus, which will inform vaccine development Credit: Image courtesy of Shannon Esswein.

Antibody 52

Antibody Scientist Vaccination Vaccine 52

Scienmag

JULY 23, 2021

Vaccines against COVID-19, which […].

Antibody 75

Antibody Protein Vaccination Vaccine 75

Scienmag

OCTOBER 2, 2020

Credit: Virginia Tech Renowned tick immunobiologist Utpal Pal wants to ad apt the rabies vaccination platform to produce antibodies that can protect against Borrelia burgdorferi, the bacteria responsible for Lyme disease. The intention is to apply this work to other tick-borne diseases in the future.

Vaccination 88

Vaccination Vaccine Bacteria Development 88

Scienmag

DECEMBER 16, 2020

Scientists at the Ragon Institute of MGH, MIT and Harvard find that neutralizing antibody potency predicts severe or fatal COVID-19. BOSTON — Understanding the body’s immune response to SARS-CoV-2, the virus that causes COVID-19, is key to developing effective treatments and long-lasting vaccines.

Antibody 40

Antibody Immune Response Scientist Vaccination 40

Scienmag

AUGUST 17, 2020

. — University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use.

Antibody 50

Antibody Scientist Vaccination Vaccine 50

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Scienmag

MARCH 31, 2021

New findings from a Michigan Medicine study reveal that antibody testing is predictive of prior COVID-19 infection, and rapid screening methods – even from finger pricks – are effective testing tools. Researchers analyzed antibody tests conducted on more than 500 subjects […].

Antibody 40

Antibody Medicine Research Clinical Trials 40

Scienmag

JANUARY 10, 2021

January 11, 2021) – To build better vaccines, scientists want to know more about how our bodies make adequate numbers of effective, durable antibodies against the influenza virus. Credit: Kim Ratliff, Augusta University AUGUSTA, Ga.

Vaccination 59

Vaccination Vaccine Antibody Scientist 59

Scienmag

JANUARY 25, 2021

OHSU study has important implications for vaccines, diagnosis of COVID-19 A new study demonstrates that antibodies generated by the novel coronavirus react to other strains of coronavirus and vice versa, according to research published today by scientists from Oregon Health & Science University.

Antibody 40

Antibody Scientist Vaccination Vaccine 40

Scienmag

MARCH 5, 2021

Scientists at Walter Reed Army Institute of Research, in a collaboration the Duke University, have confirmed that monoclonal antibodies can be an effective tool in the global fight against malaria.

Scientist 74

Scientist Antibody Research Allergies 74

Scienmag

NOVEMBER 6, 2020

New study demonstrates candidate’s potential to generate antibodies, limit viral shedding Credit: Craig Chandler, University of Nebraska-Lincoln A genetically edited form of a herpes simplex virus — rewired to keep it from taking refuge in the nervous system and eluding an immune response — has outperformed a leading vaccine candidate (..)

Vaccination 49

Vaccination Vaccine Immune Response Genetics 49

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. The two drugs combined with radiation cleared the brain metastases in 75% of the animals, as reported in the journal Science Translational Medicine.

Vaccination 53

Vaccination Vaccine Research Trials 53

Scienmag

JULY 6, 2021

Studies reveal unprecedented mechanism behind loss of antibody neutralization against this pandemic coronavirus variant of concern Credit: Young-Jun Park, UW Department of Biochemistry Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced by current vaccines or past COVID infections.

Antibody 98

Antibody Protein Vaccination Vaccine 98

Scienmag

JANUARY 7, 2021

ANN ARBOR–A team of researchers has discovered an antibody that blocks the ability of the dengue virus to cause disease in mice. The findings open the potential for developing effective treatments and designing a vaccine for dengue and similar diseases.

Antibody 40

Antibody Research Vaccination Vaccine 40

Scienmag

SEPTEMBER 4, 2020

The new paper reports the findings of two open-label, non-randomised phase 1/2 trials looking at a frozen formulation and a freeze-dried formulation of a two-part vaccine.

Vaccination 45

Vaccination Vaccine Trials Antibody 45

Scienmag

FEBRUARY 10, 2021

Antibodies that react to both ordinary coronaviruses and SARS-CoV-2 are common in the population but don’t neutralize the COVID-19-causing virus PHILADELPHIA — Past exposure to seasonal coronaviruses (CoVs), which cause the common cold, does not result in the production of antibodies that protect against the novel coronavirus SARS-CoV-2, (..)

Antibody 45

Antibody Production Allergies Vaccination 45

Scienmag

NOVEMBER 3, 2020

Brigham investigators have identified patients who cleared the disease faster and had a persistent antibody response, with important implications for immunity Boston, MA — One of the pressing questions about COVID-19 remains: How long does immunity last? One key indicator of immunity is the presence of virus-specific antibodies.

Antibody 43

Antibody Allergies Vaccination Vaccine 43

Scienmag

MAY 18, 2021

An imaging technique pioneered by Berkeley Lab is helping reveal the best antibodies for COVID-19 detection Credit: (Credit: Berkeley Lab) Vaccines are turning the tide of the pandemic, but the risk of infection is still present in some situations. If you want to visit a friend, get on a plane, or go see a movie, […].

Antibody 86

Antibody Vaccination Vaccine Allergies 86

Scienmag

MAY 13, 2021

New study suggests COVID vaccines may still be helpful for patients with antibody deficiency disorders According to data from a cohort of adult and pediatric patients with antibody deficiencies, patients that often fail to make protective immune responses to infections and vaccinations showed robust T-cell activity and humoral immunity against SARS-CoV-2 (..)

Immune Response 53

Immune Response Antibody Protein Vaccination 53

The Pharma Data

DECEMBER 8, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 .–(BUSINESS WIRE)–Dec. 8, 2020– Moderna, Inc.,

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40

Pfizer

JULY 19, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 1 Adapted Bivalent Vaccine Candidate. 1 as compared to the companies’ current COVID-19 vaccine.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. This new study will complement Mymetics’ other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.

Vaccination 40

Vaccination Vaccine Containment Immune Response 40

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” mg dose group and 84% demonstrating neutralizing antibodies in the 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Scienmag

OCTOBER 23, 2020

The technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.

Protein 61

Protein Antibody Scientist Vaccination 61

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. Singapore biotechnology company.

Immune Response 52

Immune Response Protein Medicine Genetics 52

Scienmag

DECEMBER 22, 2020

Study provides insights that could inform vaccine timing and improve care BOSTON — Pregnant women may be especially vulnerable to developing more severe cases of COVID-19 following SARS-CoV-2 infection, but little is known about their anti-SARS-CoV-2 immune response or how it may affect their offspring.

Immune Response 40

Immune Response Antibody Vaccination Vaccine 40

Scienmag

MAY 13, 2021

Scientists at the Ragon Institute of MGH, MIT and Harvard discover epigenetic changes unique to B cells and B cell subtypes BOSTON – B cells are the immune cells responsible for creating antibodies, and most B cells, known as B2 cells, produce antibodies in response to a pathogen or a vaccine, providing defense and immunity […].

Antibody 40

Antibody Scientist Vaccination Vaccine 40

Drug Discovery World

JANUARY 24, 2024

Three different HIV antibodies each independently protected monkeys from acquiring simian-HIV (SHIV) in a placebo-controlled proof-of-concept study intended to inform development of a preventive HIV vaccine for people. 15 acquired SHIV, and 25% of those receiving the antibody called DF1W-a.01 Among monkeys that received VRC34.01

Antibody 52

Antibody Vaccination Vaccine Allergies 52

pharmaphorum

SEPTEMBER 29, 2022

The disorder – driven by type 2 inflammation characterised by an antibody-based immune response – causes hard lumps or nodules to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Drugs 69

Drugs Immune Response Allergies Sales 69

The Pharma Data

MARCH 22, 2021

79% vaccine efficacy at preventing symptomatic COVID-19. The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo.

Trials 52

Trials Vaccination Vaccine Radiology 52

Scienmag

SEPTEMBER 11, 2020

Individuals’ immunological imprint from early childhood infection likely lessens severity but does not prevent infection September 11, 2020 PHILADELPHIA — Penn Medicine researchers have found that middle-aged individuals — those born in the late 1960s and the 1970s — may be in a perpetual state of H3N2 influenza virus susceptibility (..)

Antibody 45

Antibody Medicine Research Allergies 45

The Pharma Data

MARCH 24, 2021

76% vaccine efficacy against symptomatic COVID-19. Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. 100% efficacy against severe or critical disease and hospitalisation.

Radiology 52

Radiology Vaccination Vaccine Trials 52

Pfizer

SEPTEMBER 28, 2022

Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5-Adapted 5-adapted bivalent vaccine. 5) AUTHORIZED USES .

Vaccination 101

Vaccination Vaccine Medicine Clinical Trials 101

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Scienmag

NOVEMBER 4, 2020

Stopping emerging viruses could depend on getting T cells and antibodies to work together Credit: NIAID LA JOLLA–Where Aedes mosquitoes fly, Zika virus may not be far behind.

Antibody 95

Antibody Allergies Vaccination Vaccine 95